AtaiBeckley Inc. (ATAI) has a MoatMap StockRank of 17/100 based on Quality (26/100), Value (33/100), and Momentum (43/100) factor scores. The current signal is STRONG SELL. A clinical-stage biopharmaceutical company focused on psychedelic treatments. It is highly speculative, pre-revenue, and does not align with our CDMO pricing power theme.
Atai Life Sciences N.V. (ATAI) is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for mental health disorders, including depression, anxiety, and substance use. The company employs a decentralized platform model to identify, invest in, and advance a diverse pipeline of psychedelic and non-psychedelic compounds. This strategic approach aims to accelerate the development of innovative treatments for unmet medical needs in psychiatry.
| Price | $3.89 |
| Market Cap | $1.6B |
| P/E (Forward) | -9.89 |
| Price/Book | 8.09 |
| Return on Equity | -378.0% |
| Return on Invested Capital | -244.6% |
| Debt/Equity | 1.01 |
| Gross Margin | 0.0% |
| Operating Margin | -3239.1% |
| Revenue Growth | -38.7% |
AtaiBeckley Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).